Celgene In Licensing "Discussions" On Thalomid Risk Management Patents
This article was originally published in The Pink Sheet Daily
Executive Summary
Thalidomide STEPS program patents and increasing emphasis on restricted drug distribution systems create "potential licensing and revenue opportunities," Celgene says. The patents are blocking implementation of revised risk management plans for Accutane and isotretinoin generics.